Impact of bladder cancer on health‐related quality of life

Smith, Angela; Jaeger, Byron C.; Pinheiro, Laura C.; Edwards, Lloyd J.; Tan, Hung‐Jui; Nielsen, Matthew E.; Reeve, Bryce B.

doi:10.1111/bju.14047

Cited by 122 publications

(88 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to recognize that people with bladder cancer may have a different baseline HRQoL compared with the general population, as the disease may have already had an impact at or around the time of diagnosis. No reference data are available for the general population in the UK; however, the mean scores of HRQoL (QLQ-C30) for the present study population were lower than data for the general populations of Germany, Norway, Sweden and Slovenia [30][31][32][33], but higher than the general population of the USA [34]. It is therefore, possible that HRQoL reference values for patients with bladder cancer depend on cultural factors; for example, Scandinavian populations have a high standard of living [35].…”

Section: Discussionmentioning

confidence: 61%

Health‐related quality of life around the time of diagnosis in patients with bladder cancer

Nekeman

Billingham

et al. 2019

BJU International

View full text Add to dashboard Cite

ObjectivesTo quantify the health‐related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two‐factor model for the HRQoL questionnaire QLQ‐C30.MethodsFrom participants in the Bladder Cancer Prognoses Programme, a multicentre cohort study, sociodemographic data were collected using semi‐structured face‐to‐face interviews. Answers to the QLQ‐C30 were transformed into a scale from 0 to 100. HRQoL data were analysed in multivariate analyses. The hypothesized two‐factor (Physical and Mental Health) domain structure of the QLQ‐C30 was also tested with confirmatory factor analyses (CFA).ResultsA total of 1160 participants (78%) completed the questionnaire after initial visual diagnosis and before pathological confirmation. Despite non‐muscle‐invasive bladder cancer (NMIBC) being associated with a higher HRQoL than carcinoma invading bladder muscle, only the domain Role Functioning was clinically significantly better in patients with NMIBC. Age, gender, bladder cancer stage and comorbidity all had a significant influence on QLQ‐C30 scores. The CFA showed an overall good fit of the hypothesized two‐factor model.ConclusionThis study identified a baseline reference value for HRQoL for patients with bladder cancer, which allows better evaluation of any changes in HRQoL as disease progresses or after treatment. In addition, a two‐factor (Physical and Mental Health) model was developed for the QLQ‐C30.

show abstract

Section: Discussionmentioning

confidence: 61%

Health‐related quality of life around the time of diagnosis in patients with bladder cancer

Nekeman

Billingham

et al. 2019

BJU International

View full text Add to dashboard Cite

show abstract

“…At our own institution, we have found that HRQoL significantly declines in patients with bladder cancer after diagnosis relative to controls, with more pronounced decrements seen in patients with MIBC [5]. Patients with bladder cancer are a vulnerable population who face many medical and personal challenges.…”

Section: How Can We Motivate Patients With Bladder Cancer To Help Thementioning

confidence: 91%

How can we motivate patients with bladder cancer to help themselves?

2020

Self Cite

View full text Add to dashboard Cite

“…Patients with bladder cancer can be divided into patients with muscle-invasive bladder cancer (MIBC, Stages II to IV), disease that mainly requires radical surgical treatment and chemoradiation, and patients with the less severe non-muscle-invasive bladder cancer (NMIBC, Stage I). For NMIBC, long-term surveillance with periodic cystoscopy is often required with heavy effects on patients' quality of life [5]. Moreover, the high recurrence rate and ongoing invasive monitoring requirements are the key contributors to the economic and human toll of this disease.…”

Section: Introductionmentioning

confidence: 99%

Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage

Vago

Ravelli

Bettiga

et al. 2020

Cancers

View full text Add to dashboard Cite

Due to the involvement of the endocannabinoid system (ECS) in cancer onset and progression and the less studied connection between ECS and bladder cancer, here an evaluation of the ECS modifications associated with bladder cancer is reported. Urine samples were collected from healthy volunteers and patients with bladder cancer at different grades. Endocannabinoids (ECs) and N-acylethanolamides (NAEs) were quantified by HPLC-MS/MS and results normalized for creatinine content. An increase in the urine concentrations of four ECs and NAEs analyzed was observed with a statistically significant increase in the arachidonoylethanolamide (AEA) and stearoylethanoamide (SEA) associated with bladder cancer. Receiver operating characteristic curves built with AEA and SEA data allowed the selection of 160 pg/mL for SEA (area under the curve (AUC) = 0.91, Selectivity (SE) 94%, Specificity (SP) 45%) and 8 pg/mL for AEA (AUC = 0.85, SE 94%, SP 61%) as the best cut-off values. Moreover, data from bladder cancer samples at different grades were derived from The Cancer Genome Atlas, and the expressions of thirteen different components of the “endocannabinoidome” were analyzed. Statistical analysis highlights significant variations in the expression of three enzymes involved in EC and NAE turnover in bladder cancer.

show abstract

Impact of bladder cancer on health‐related quality of life

Cited by 122 publications

References 33 publications

Health‐related quality of life around the time of diagnosis in patients with bladder cancer

Health‐related quality of life around the time of diagnosis in patients with bladder cancer

How can we motivate patients with bladder cancer to help themselves?

Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage

Contact Info

Product

Resources

About